Microinjection platform enables assessment of multiple cancer drugs directly in tumors
Presage Biosciences - 22-Apr-2015Results from first-in-human study in lymphoma patients confirm feasibility for toxicity-sparing a...
Rajesh Chopra
Head of the Division of Cancer Therapeutics, Institute of Cancer Research and Royal Marsden Hospital.
Raj Chopra trained in medicine at University College London. He then completed his training in general medicine at major teaching hospitals in London, gaining a Membership of the Royal College of Physicians. He undertook a Ph.D. in cell signaling and growth receptors followed by a post doctoral fellowship at The Walter and Eliza Hall Institute in Melbourne, Australia. There he worked for Professor D. Metcalf who was the first to culture human hematopoietic stem cells and discover both G- and GM-CSF. He then worked with Professor M. Dexter (latterly Director of the Wellcome Trust) setting up his own research group on Stem Cell Biology.
At the same time he was appointed Director of Hematological Oncology, leading one of the largest bone marrow transplant and leukemia programs in Europe at The Christie Hospital in Manchester.
From 2004 to 2009, Raj was part of the leadership team for the largest oncology team in AstraZeneca and established Translational Medicine for AZ in Boston, MA. He was involved in taking 6 small molecules and 2 antibodies into clinical trials from discovery.
See also: 
The Institute of Cancer Research (ICR)
- One of the world’s most influential cancer research organizations
Details last updated 28-Jul-2020
Rajesh Chopra News
